KaloBios in Agreement to Buy Former CEO Shkreli’s Shares

  • CEO says company aims for ‘revitalizing its reputation’
  • KaloBios pledges transparent, responsible pricing of drugs

KaloBios Pharmaceuticals Inc. said it has an agreement with Martin Shkreli, the company’s former chief executive officer who came under fire for raising drug prices, to buy back his shares and restrict his shareholder actions, in a move to cut ties with the controversial investor.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.